Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral
infections. The purpose of this study is to test the safety and antiviral effects of
PEG-rIL-29 (a man-made form of IL-29) when it is given either by itself at different doses or
in combination with the approved dose of ribavirin (an antiviral drug) to subjects with
hepatitis C infection who have received no prior treatment for this disease or who have
relapsed following previous treatment with PEGylated interferon alpha (PEG-IFN-α), or other
form of IFN-α, and ribavirin.